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fear expression is suppressed by 
tyrosine administration
Alessandro Soranzo & Luca Aquili*
Animal studies have demonstrated that catecholamines regulate several aspects of fear conditioning. in 
humans, however, pharmacological manipulations of the catecholaminergic system have been scarce, 
and their primary focus has been to interfering with catecholaminergic activity after fear acquisition 
or expression had taken place, using L-Dopa, primarily, as catecholaminergic precursor. Here, we 
sought to determine if putative increases in presynaptic dopamine and norepinephrine by tyrosine 
administered before conditioning could affect fear expression. Electrodermal activity (EDA) of 46 
healthy participants (24 placebo, 22 tyrosine) was measured in an instructed fear task. Results showed 
that tyrosine abolished fear expression compared to placebo. Importantly, tyrosine did not affect EDA 
responses to the aversive stimulus (UCS) or alter participants’ mood. Therefore, the effect of tyrosine on 
fear expression cannot be attributed to these factors. Taken together, these findings provide evidence 
that the catecholaminergic system influences fear expression in humans.
Pavlovian fear conditioning is a valuable behavioural paradigm suitable for neurobiological and physiological 
analyses1 in both animals and humans. Typical fear conditioning protocols in animals consist of presenting a 
conditioned stimulus (CS) followed by an aversive stimulus (UCS), in a process described as fear acquisition. In 
humans, fear conditioning protocols can also be “instructed” where explicit instructions about CS-UCS contin-
gencies are provided prior to testing. To distinguish between uninstructed and instructed protocols, some authors 
have suggested to refer to the former as measuring fear acquisition and to the latter as fear expression2, in that 
learning can already take place in the instruction phase. In the animal literature, however, the term fear expression 
is used to describe conditioned responses (CR) that have developed following fear acquisition when the CS is 
presented in the absence of the UCS.
Using the Pavlovian paradigm, a growing body of literature has indicated the catecholaminergic system as 
playing a significant role in the acquisition, expression and extinction of fear responses. Animal studies have 
demonstrated the involvement of dopaminergic D1, D2, D3 and D4 receptors in the amygdala in fear condition-
ing. D1 and D2 antagonists block the acquisition of fear memories3–7 whilst the administration of D1 or D2 ago-
nists increase fear expression8,9. Blockade of D3 receptors has, surprisingly, shown to enhance fear acquisition10, 
whilst D4 activation potentiates acquisition11. In humans, the effects of a dopamine reuptake blocker (Ritalin) 
or a dopamine precursor (L-Dopa) have only been investigated with respect to fear extinction and spontaneous 
recovery12,13, but not fear acquisition.
Animal studies have also revealed an important role of norepinephrine (NE) in fear conditioning (for an 
extensive review, please see14). Administration of the non-selective β-adrenergic receptor antagonist propanol 
prior to training impairs fear acquisition15,16. Similarly, administration of the selective α2-adrenergic agonist 
dexmedetomidine (which decreases activity of NE neurons), weakened cued conditioning17. Genetic studies in 
which NE was reduced, enhanced, or eliminated as in knockout investigations have revealed a more complex 
picture with respect to the role of NE in fear acquisition16–18.
Overall, despite some complex interaction effects, there is robust evidence to suggest that dopamine and nor-
epinephrine are involved in the acquisition/expression of fear responses.
In humans, investigations of dopamine and norepinephrine have been scarce, and have largely focused on the 
study of extinction, extinction consolidation and reconsolidation processes19–28, or in those with posttraumatic 
stress disorder29,30. In these studies, catecholaminergic activity was manipulated after fear conditioning had taken 
place. However, given the existing animal literature, catecholaminergic activity may also be important in regu-
lating fear acquisition and/or expression. To understand whether fear expression is affected, one would need to 
manipulate dopamine and norepinephrine tone before conditioning. Moreover, previous studies were limited to 
testing the effects of L-Dopa as a catecholaminergic precursor.
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In this research, we set out to answer: (i) whether alterations in catecholaminergic tone before conditioning 
would affect fear expression and (ii) whether a different catecholaminergic precursor to L-Dopa namely tyrosine 
would modulate this effect.
There are good theoretical reasons for the use of tyrosine rather than L-Dopa. The conversion mechanism of 
tyrosine to dopamine and norepinephrine is restricted to by competition from other endogenous amino acids 
and by the rate-limiting tyrosine-hydroxylase enzyme whilst L-Dopa is not31. As a result, these restrictions would 
limit the overall enhancement in dopamine and norepinephrine levels from tyrosine. This is important given that 
low or high doses of drugs that alter dopamine and norepinephrine levels enhance or impair fear conditioning 
respectively32,33.
Here, in a randomized, double-blind study, we tested the effects of tyrosine (placebo controlled) administered 
before fear conditioning. To test the experimental hypothesis that administration of tyrosine would enhance fear 
expression, skin conductance responses (SCR) were measured in 46 healthy volunteers while undertaking a fear 
conditioning task.
Results
ScR magnitudes in fear expression. Skin conductance responses (SCR) have been used to measure the 
effects of tyrosine and of placebo (cellulose) administration in a fear conditioning task. Drug administration 
occurred 60 minutes before fear conditioning. The task had a fear expression phase during which a conditioned 
stimulus (CS+) predicted the occurrence of an unconditioned stimulus (UCS: 75 db loud beep played through 
a pair of earphones) whereas another conditioned stimulus predicted the occurrence of a neutral event (CS−, 
which was a fixation dot, Fig. 3A). CS+ and CS− were paired six times. Responses were analysed on a trial by 
trial basis.
A 2 × 2 × 6 factorial mixed analysis of variance was conducted on SCR magnitudes during the fear expression 
phase. The between group variable, drugs, having two levels (placebo, tyrosine) the first within subject variable, 
stimulus, having two levels (CS+, CS−), and the second within subject variable, trial, having six levels (trial 1–6). 
There was neither a significant main effect of drugs, F (1, 44) = 0.721, p = 0.400, η2 = 0.016, nor a main effect of 
stimuli, F (1, 44) = 1.678, p = 0.202, η2 = 0.037, nor a trial × drugs, F (5, 44) = 1.781, p = 0.118, η2 = 0.039, nor a 
trial × drugs × stimuli significant interaction, F (5, 44) = 0.664, p = 0.651, η2 = 0.015.
There was, however, a significant main effect of trial, F (1, 44) = 9.342, p < 0.001, η2 = 0.175, a significant 
trial × stimulus interaction, F (3.8, 167) = 3.719, p = 0.017, η2 = 0.067, and most importantly, a significant 
drugs × stimuli significant interaction, F (5, 44) = 4.306, p = 0.044, η2 = 0.089 (see Fig. 1A).
To break down this significant interaction, planned comparisons demonstrated that in the placebo group, 
there were significantly higher SCRs for CS+ than CS−, t (23) = 3.612, p = 0.001, d = 0.73, however this was not 
the case in the tyrosine group, t (23) = 0.427, p = 0.674, d = 0.13. When comparing SCRs for CS+ between the 
placebo and tyrosine group, significantly higher fear responses occurred for the placebo than tyrosine group, t 
(44) = 2.914, p = 0.006, d = 0.92, whilst no significant differences were reported for CS−, t (44) = 0.470, p = 0.641, 
d = 0.13 (see Fig. 1B). These findings therefore demonstrate that tyrosine impairs fear expression.
Control measures: SCR magnitudes during UCS. We checked whether tyrosine effects on fear condi-
tioning could be ascribed to an association between CS+ and UCS, as opposed to unspecific systemic effects on 
UCS alone. We therefore conducted a drugs × time mixed ANOVA of the responses to the UCS.
There was a significant main effect of time (F (1, 44) = 16.89, p < 0.001, η2 = 0.277). This indicates that SCRs 
to UCS decreased over time regardless of the drug (see Fig. 2A). Importantly, there was neither a main effect 
of drugs (F (1, 44) = 0.001, p = 0.985, η2 = 0.000) nor a time × drugs significant interaction (F (1, 44) = 0.632, 
p = 0.431, η2 = 0.014).
Control measures: mood, double blinding efficacy and fear ratings. Transient changes in mood 
state have been demonstrated to influence fear learning expression34. We therefore administered a visual analogue 
scale (VAS) questionnaire before and after drug administration (but before fear conditioning: see Fig. 3B). We 
also checked whether the double blinding procedure of tyrosine/placebo administration had been effective.
There was neither a significant main effect of drugs on mood scores (F (1, 44) = 0.004, p = 0.951) nor a 
drugs × time interaction on mood scores (F (1, 44) = 1.54, p = 0.220). The probability of participants guessing the 
correct drug (placebo or tyrosine) was below chance at 39% (42% for placebo and 36% for tyrosine).
In a separate control experiment, fear/valence ratings to CSs (CS+ and CS−) were evaluated using an addi-
tional computerized VAS with values ranging from 0 (no fear/stress/tension) to 100 (maximal fear/stress/tension) 
(see Procedures), as per administered by Haaker et al.35.
There was neither a significant main effect of block on VAS fear ratings (F (1, 17) = 3.73, p = 0.070), nor a 
block × stimuli significant interaction (F (1, 17) = 1.332, p = 0.264). Importantly, there was a significant main 
effect of stimuli (F (1, 17) = 417.4, p =  < 0.001), demonstrating robust conditioning effects to the CS+ (Fig. 2B).
In a second control experiment, participants (N = 21) were asked to rate the perceived aversiveness of the UCS 
based on three dimensions, unpleasantness, intensity, and how startled they were (see Procedures), as per previ-
ously published protocols36. Participants rated the UCS as unpleasant (M = 76.2, SD = 6.1), intense (M = 68.4, 
SD = 6.6), and were moderately to strongly startled (M = 74.2, SD = 8.2), demonstrating the overall perceived 
aversiveness of the UCS (Fig. S1).
ScR magnitudes in extinction. As tyrosine blocked fear expression, we cannot interpret its effects in extinc-
tion and we report these results only for completeness in the supplementary file, together with its Figure. (S2).
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Discussion
Numerous studies over the last decade have demonstrated an involvement of dopamine and norepinephrine in 
both fear acquisition, expression and extinction. Most of these investigations have been carried out in rodents. In 
humans, work has been limited to manipulations of catecholaminergic activity post fear acquisition learning and 
hence focusing on extinction, extinction consolidation and reconsolidation processes only.
This work provides novel evidence that a catecholaminergic precursor administered before conditioning abol-
ishes fear expression. Specifically, augmentation of putative dopamine and norepinephrine levels by tyrosine 
administration rendered SCR responses to CSs in expression indistinguishable from one another (i.e. SCRs mag-
nitudes to CS+ and CS− were approximately equal and cancelled each other out: see Fig. 1A,B). Moreover, SCRs 
to CS+ were greater in the placebo group than in those administered tyrosine. Importantly, tyrosine administra-
tion did not alter processing of UCS information (see Fig. 2A) demonstrating that tyrosine selectively weakened 
CS+ UCS associations. Moreover, there were no unspecific systemic changes of tyrosine administration on meas-
ures of mood and alertness, which may have affected fear expression.
Figure 1. (A) Line chart representing skin conductance responses measured in magnitudes across trials (1–6), 
based on SCR responses to CS+ and CS− in the placebo and tyrosine groups during the fear expression phase. 
(B) Bar chart highlighting the stimuli × drugs significant interaction. Vertical lines represent standard error of 
the mean. *p = <0.05, **p =  < 0.01, ***p = 0.001.
Figure 2. (A) Line chart representing skin conductance responses to UCS measured in magnitudes during 
early and late trials in the placebo and tyrosine groups. (B) Fear ratings to CS+/CS− measured using a Visual 
Analogue Scale during expression in a second experiment.
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It is worthwhile discussing the learning curve observed in the fear instructed paradigm. As can be seen in 
Fig. 1, fear responses to CSs decreased over time. Although this pattern is common in human studies20,37–39, it is 
the opposite in animals’ studies4,8, in which fear responses increase over time.
There are a number of potential factors that can account for this phenomenon. These factors include the type 
of CS used, UCS identity and intensity, the length of inter-trial and inter-stimulus interval, the reinforcement 
rate, the trial number and order, the CS/UCS duration, the type of instructions (e.g. explicit CS-UCS contingency 
or not), whether the UCS was experienced prior to testing (i.e. UCS calibration), and variations in acquisition 
procedures (e.g. single-cue vs differential protocols; multiple-cue protocols) (for a more thorough review, see23).
Our findings that tyrosine abolished fear expression are important and surprising given that in the animal lit-
erature, increased fear acquisition and expression has been reported when a dopaminergic D1 agonist was admin-
istered8,9 or abolished when D1/D2 receptors were blocked3–6. Similar results have been reported with respect to 
manipulations of norepinephrine14–17. These contrasting findings may partially be explained by methodological 
differences in manipulating dopaminergic and norepinephrine activity postsynaptically in animal studies and 
presynaptically in the current study. It is also plausible, though speculative at present that tyrosine administration 
may have interfered with the process of prediction error signalling. The strength of this signal would have been 
greatest in early trials, when the occurrence of the UCS is most surprising40 and learning (of the CS-UCS pairing) 
is most likely to occur41,42. Midbrain dopaminergic neurons have long been known to convey a prediction error 
signal for rewards43,44, but more recent evidence also demonstrate a role for aversive events45–47. Nevertheless, 
because we employed an instructed fear conditioning protocol, the UCS presentation in the early trials should not 
have been very surprising, given that participants had been made aware of what to expect. Therefore, it is perhaps 
more plausible to suggest that differences between the animal literature and our current finding, relate to the use 
of an instructed fear paradigm. Previous research, in humans, has suggested that uninstructed fear conditioning 
paradigms (as in most animal studies) recruit a differential neuronal circuitry to that of instructed fear studies48.
With respect to human studies, our findings cannot directly be compared to previous investigations, especially 
those that manipulated dopaminergic activity after fear acquisition had taken place and investigated extinction 
and extinction consolidation. Onur et al. manipulated norepinephrine levels before conditioning. In their study, 
administration of the NE reuptake inhibitor reboxetine induced an amygdala response bias towards fear signals49. 
Similarly, Visser et al. reported a rise in salivary-amylase levels (a marker of markers of noradrenergic activation) 
prior to fear conditioning which correlated with fear consolidation expression50. Taken together, in humans, 
increasing catecholamines (using tyrosine) before fear conditioning impairs fear expression whilst pharmacologi-
cal augmentation of norepinephrine before conditioning enhance fear acquisition. In animals, targeted manipula-
tions of both dopamine and norepinephrine that either increase or decrease their release before fear conditioning 
enhance and impair acquisition learning respectively.
The choice of administering tyrosine instead of L-Dopa as in past studies was motivated by a number of rea-
sons. Firstly, conversion of tyrosine into dopamine (and other catecholamines) is restricted by the transporter 
shared with other amino acids and by the rate-limiting TH enzyme. L-Dopa, on the contrary, is not affected by 
these and its administration would result in greater concentrations being converted to catecholamines31. However, 
given the well-established inverted U relationship between dopamine concentration and performance51, it is fore-
seeable that L-Dopa would be more likely than tyrosine to shift participants at the right end of the curve. This 
would be particularly the case in individuals who are homozygous for the Met/Met allele on the Val(108/158)Met 
COMT polymorphism, and possess higher baseline dopaminergic activity52. Secondly, an additional advantage 
of administering tyrosine is that it produces fewer and less severe side effects than L-Dopa (e.g. nausea, insomnia, 
psychosis)53.
As tyrosine is the precursor for dopamine, norepinephrine (noradrenaline) and epinephrine it can be con-
cluded that these neurotransmitters are involved in fear expression. Finally, it is worth considering the impli-
cations of our data in the context of the pathogenesis of anxiety disorders. Two large meta-analyses54,55, looked 
at fear conditioned responses of healthy and anxiety patients to CS+, CS− and the conditioned response (CR) 
difference between (CS+) - (CS−). Contrary to theories by Davies and colleagues56, who suggested that healthy 
individuals would produce higher CRs to (CS+) than (CS−) compared to anxious individuals in acquisition, 
the data from the meta-analyses demonstrated that this was not the case. Similarly, the meta-analyses found no 
significant differences in responding to CS+ between healthy and anxious patients. Importantly, it was found 
that responding to the conditioned safety cue (CS−) was higher in anxious patients compared to healthy con-
trols. These results suggest that any pharmacological agent with anxiolytic properties should reduce conditioned 
responses to CS− in anxious patients to match those of controls, and that in healthy participants the pharmaco-
logical agent would reduce even further conditioned responses to the safety cue compared to a placebo group.
Based on our data, we conclude that tyrosine did not have such anxiolytic properties, but rather, that impaired 
fear expression responses.
Limitations and future directions. Although we established that catecholamines contributed to 
fear expression, our study did not set out the reveal the neuronal pathways that would have determined this 
effect. Therefore, future investigations using imaging techniques (e.g. PET) would be required to under-
stand how changes in dopamine/norepinephrine in brain regions of interest regulate fear expression (e.g. 
amygdala-prefrontal cortex). Furthermore, to obtain greater specificity with respect to dopamine for example, 
one would need to co-administer a noradrenergic blocker such as Clonidine together with tyrosine/L-Dopa, or 
target D1/D2 receptors. More crudely, reducing catecholaminergic neurotransmission using the acute phenylala-
nine/tyrosine procedure57 before conditioning, would provide a potential counter test for the effects of manipu-
lating catecholamines on fear expression.
In conclusion, our results provide evidence that manipulating catecholaminergic tone before conditioning in 
humans can suppress fear expression.
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Method
participants. Participants consisted of 46 university students (M = 20.4, SD = 1.7; 25 females and 21 males). 
The study was approved by the ethics committee of Sheffield Hallam University (SHU) and complied with the 
Declaration of Helsinki. All study methods were performed in accordance with SHU guidelines. Informed con-
sent was obtained for all participants before testing could take place. Exclusion criteria included: those suffering 
from cardiac, hepatic, renal and neurological disorders and individuals with a history of alcohol or drug addic-
tion, or psychiatric illness. Individuals having a history of taking tyrosine supplements were also excluded.
Drug administration. Participants received either 2.0 g of l-Tyrosine (supplied by BulkPowders Ltd.) or 
2.0 g of the placebo microcrystalline cellulose (Redwells Creative Limited,UK) dissolved in 400 ml of orange juice 
as per previously published protocols58,59. Dosages greater than 2.0 grams have been shown not to provide addi-
tional benefits given that the rate-limiting tyrosine hydroxylase (TH) enzyme is already close to saturation under 
normal circumstances60. Peak plasma tyrosine levels have been reported to occur between 60 and 120 minutes 
post-ingestion61. In rats, increases in prefrontal dopamine concentrations can be observed 60 minutes following 
tyrosine administration62.
electrodermal activity recording. Physiological recording were obtained using a BIOPAC MP150 data 
acquisition unit (Biopac Systems Inc., Santa Barbara, CA), and AcqKnowledge 4.4 software. Electrodermal activity 
(EDA) data were collected at 2000 samples/sec. Two disposable latex-free electrodes (EL507, BIOPAC) contain-
ing isotonic gel were attached to the distal phalanges of the index and middle fingers of the non-dominant hand. 
The EDA signal was then enhanced by a wireless BioNomadix ® amplifier. Skin conductance responses (SCR) 
threshold was set at 0.01 microSiemens (µS) with SCR onsets and peaks (i.e. a measure of change in tonic EDA) 
counted as being event related if occurring between 1–4.5 seconds following stimulus (CS+/CS−/UCS) onset. 
Data transformation of SCR magnitudes was applied using the square root (√SCR) as in previously published 
protocols63. Participants who did not produce a measurable conditioned response (i.e. classified as CS+ = SCR 
amplitude not reaching the 0.01 threshold across the whole conditioning session) (8/56), a similar criterion to 
previous reports64, were discarded from the analyses as those with poor electrode contact/motion artefacts (2/56), 
giving us a remaining sample of 46 volunteers. Of those 46, 24 participants were in the placebo condition and 22 
in the tyrosine. To confirm that the overall results were not dependent on the exclusion of these participants, we 
rerun these analyses excluding only those due to poor recording (2/56) and those who did not respond to the UCS 
(2/56) (i.e. not the outcome measure), giving us a remaining sample of 52 volunteers, 26 placebo and 26 tyrosine. 
These data (see Supplementary info) confirm the conclusions reached in the results section.
fear instructed task. The conditioning task was programmed in OpenSesame65. Visual stimuli consisted of 
blue and yellow circles either predicting an aversive stimulus (CS+) or a neutral fixation dot (CS−). These were 
presented in a counterbalanced (i.e. half of the participants had the blue circle as CS+ and the other half had the 
yellow circle as the CS+) and randomized order (i.e. the CS+/CS− sequence varied for each participant). Before 
testing began, on screen instructions told participants which of the two CSs would be paired with the aversive 
stimulus (UCS) (as in “In this experiment, the following stimulus [image 1 shown] will be followed by a loud 
beep, whilst another stimulus [image 2 shown] will be followed by a neutral fixation dot [image 3 shown]. You are 
not required to perform any actions but to remain as still as possible throughout the duration of the experiment. 
The experiment will last approximately 8 minutes”) which consisted of a loud beep (75 db measured using an 
audiometer) lasting 1000 ms delivered through headphones. Moreover, participants were not exposed to the UCS 
prior to testing. In a previous pilot study, the UCS reliably elicited SCRs in over 90% of the trials.
The task was divided into an expression and an extinction phase. Each CS presentation lasted 5000 ms with an 
intertrial interval (ITI) of 10000 ms consisting of a fixation dot. During expression, there were 6 pairings of CS+ 
and UCS (as in CS+ for 5000 ms, followed by UCS for 1000 ms and fixation dot [ITI] for 10000 ms) and 6 of CS− 
(as in CS− for 5000 ms, followed by the same fixation dot for 10000 ms). The duration of the ITI was chosen based 
on previous reports19 and permitted recovery of the SCR. In the extinction phase, both stimuli were unpaired 
(CS+ and CS− followed by the fixation dot) and presented 8 times each. The task lasted approximately 8 minutes. 
A schematic illustration of the task is shown in Fig. 3A.
Control measures: mood, double-blinding efficacy and fear ratings. We checked for the potential 
mood effects induced by tyrosine intake by administering a computerized adaptation of the visual analog scale 
(VAS) which was programmed and run in PEBL66, and has previously been used by our research group67–69. The 
scale consists of seven dimensions (e.g. boredom, sadness, relaxation, happiness, stress, alertness, calmness) of 
mood/alertness. The double-blinding efficacy of placebo/tyrosine administration was checked by a question-
naire (i.e. “Please circle whether you think you received a tyrosine containing drink (experimental) or a placebo, 
non-tyrosine containing drink (control)”) given to participants at the end of the experiment.
Fear ratings for CS+/CS− were measured in a separate cohort of participants (n = 18) using a computerized 
VAS as per previous research groups35. Briefly, after the 3rd CS+/CS− pairing, and at the end of the last trial (trials 
6 for both CS+ and CS−), participants rated each CS on a scale ranging from 0 (no fear/stress/tension) to 100 
(maximal fear/stress/tension).
Additionally, we measured in a third cohort of participants (n = 21) their perceived aversiveness to UCS pres-
entation using a similar approach to that of Hermans et al.36. Note that, as reviewed elsewhere2, there is no agreed 
consensus on the precise procedural approach to measuring aversiveness (i.e. the type of visual/verbal scale used) 
and which criterion constitutes the threshold for the UCS being perceived as aversive, with minimum (aversive-
ness) scores ranging from 5 out of 10 to 8 out of 10. Using a computerized VAS, participants rated the UCS for 
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three characteristics; the first was the unpleasantness of the stimulus, with a score of 0 being described as pleasant, 
50 neutral, and 100 unpleasant. The second was the intensity of the UCS, with 0 being classified as light, 50 intense 
and 100 intolerable. The third was how startled participants responded to the UCS, with 0 being labelled not at 
all, 50 moderately, and 100 very strongly. Participants were presented with the UCS six times, using similar timing 
intervals between each UCS as in the fear instructed study, but without CS+/CS−. After the last UCS, partici-
pants completed the VAS.
procedure. This was a double-blind, placebo-controlled, mixed design experiment. Participants were 
required to attend a session lasting approximately 75 minutes. After screening for eligibility, participants were 
instructed to refrain from eating/drinking for a minimum of 3 hours. This is to reduce competition from other 
amino acids that share the same transporter70. They first signed a consent form followed by the mood question-
naire (VAS; time 1), and were then randomly assigned to receive either tyrosine or placebo. Participants were then 
asked to rest for 50 minutes following tyrosine/placebo intake, at the end of which, EDA electrodes were attached 
to the participant’s index and middle finger. At 59 minutes (post tyrosine/placebo consumption), the VAS was 
completed for a second time (time 2). At 60 minutes, fear conditioning and EDA recording began. Participants 
were instructed to remain as still as possible during testing to reduce motion artefacts. Following this, participants 
completed the tyrosine/placebo double-blind questionnaire, and were debriefed (see Fig. 3B).
Statistical analyses. Sample size was estimated using the following parameters: power 0.8, alpha 0.05, 
mixed design ANOVA containing 2 groups, 2 repeated measurements and a large f2 effect size of 0.4 (G*Power 
3.1.9.2, Germany). The size of the effect size was based on the results of previous reports which looked at fear 
conditioning responses (SCR) using another catecholaminergic precursor (l-DOPA)20.
We performed a number of analyses on SCR measurements. First, we calculated expression responses on trial 
by trial basis (i.e. across the 6 CS+ and CS− pairings). The following variables were considered: Drugs (placebo 
and tyrosine), Trials (trial 1 to trial 6) and CS identity/stimuli (CS+, CS−). SCRs were measured 1–4.5 seconds 
following stimulus onset (CS+/CS−) which terminated after 5 second and hence did not include the UCS (which 
was presented between 5–6 seconds following CS+ onset), as in previous reports22,64, to isolate acquisition effects 
specific to the CS + and not confounded by the UCS.
Second, we run a Drug (placebo and tyrosine) × Time (early trials, and late trials) ANOVA of the responses 
to the UCS, here also measuring SCRs to UCS in the 1–4.5 seconds following stimulus (UCS) onset. This type of 
analysis has been done by other research groups71, and allows to capture UCS encoding in acquisition.
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